[1]Aznab, M., Khazaei, M., 2016. Stevens-Johnson syndrome patient received combination chemotherapy gemcitabine, cisplatin, and 5-FU for biliary tract cancer. Int. J. Cancer Manag., 9(3):e4211.

[2]Chung, W.H., Wang, C.W., Dao, R.L., 2016. Severe cutaneous adverse drug reactions. J. Dermatol., 43(7):758-766.

[3]Gravante, G., Delogu, D., Marianetti, M., et al., 2007. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients. Eur. Rev. Med. Pharmacol. Sci., 11(4):269-274.

[4]Hockett, K.C., 2004. Stevens-Johnson syndrome and toxic epidermal necrolysis: oncologic considerations. Clin. J. Oncol. Nurs., 8(1):27-55.

[5]Jones, R., Kirkup, M., Guglani, S., et al., 2006. Toxic epidermal necrolysis after PCV combination chemotherapy for relapsed B-cell lymphoma. Clin. Oncol. (R. Coll. Radiol.), 18(1):90.

[6]Schoeffler, A., Levy, E., Weinborn, M., et al., 2014. Stevens-Johnson syndrome and Hodgkin’s disease: a fortuitous association or paraneoplastic syndrome? Ann. Dermatol. Venereol., 141(2):134-140 (in French).

[7]Schwartz, R.A., McDonough, P.H., Lee, B.W., 2013. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J. Am. Acad. Dermatol., 69(2):173.e1-173.e13; quiz 185-186.

[8]Wu, J., Lee, Y.Y., Su, S.C., et al., 2015. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br. J. Dermatol., 173(5):1224-1231.

[9]Yang, C.H., Yang, L.J., Jaing, T.H., et al., 2000. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int. J. Dermatol., 39(8):621-623.

[10]Yoshifuku, K., Nishimoto, K., Matsuzaki, T., et al., 2015. A case of Stevens-Johnson syndrome developing during chemoradiotherapy for maxillary sinus cancer. Nihon Jibiinkoka Gakkai Kaiho, 118(12):1436-1442 (in Japanese).

Open peer comments: Debate/Discuss/Question/Opinion
<1>